+34 679 490 537info@nanbiosis.com

Nanbiosis

U1. Protein Production Platform Unit (PPP)

Ciber bbn

U1. Protein Production Platform (PPP)

U1. PPP logo IBB UAB
Order request

Description

The PPP Unit is at the Institute of Biotechnology and biomedicine of the Autonomous University of Barcelona (IBB-UAB) and counts with the necessary facilities for the design, production and purification of recombinant proteins. This facility is coordinated by the Nanobiotechnology Group, leaded by Prof. Antonio Villaverde. It has both highly specialized personnel and the necessary equipment to offer an “tailored” service for the design, production and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems. Its location allows this service to be linked with other complementary services available within the university (Cell Culture, Cytometry, Production of Antibodies, Microscopy, Proteomic, and Bioinformatic,X-ray crystallography, and the Microarray and Sequencing Services), as well as facilitating the management of subsequent uses of the produced protein.

Counts with a laboratory perfectly equipped for the bioproduction of proteins, other with all the necessary equipment for the molecular cloning, plus one lab for the purification and characterization, and finally one for cryopreservation.

The PPP Unit is also applying for the ISO9001 certification forstandard quality control system.

IQNet ISO 9001:2015 Certification PPP

AENOR ISO 9001:2015 Certification PPP

Active projects

TitleFundin: OrganismCall: Funding source Role
GA: 720942SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-FabryUnión Europea (Comisión Europea)H2020-NMBP-2016-2017Coordinator
SAF2017-90810-REDIStrategic Promotion and coordinated management of Nanbiosis: Pronanbiosis IIAgencia Estatal de Investigación (AEI)Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017Coordinator

Other projects

RefTitleFunding OrganismUnit Role
PI15/00272Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer.Instituto de Salud Carlos IIIParticipant
BIO2013-41019-PENGINEERING OF PROTEIN NANOPARTICLES FOR THE DIRECT DELIVERY OF THERAPEUTIC PROTEINS AND NUCLEIC ACIDSMINECOParticipant
2014SGR-132Basic and Applied MicrobiologyAGAURParticipant
BIO2016-76063-RDEVELOPMENT OF NONOSTRUCTURED PROTEIN TOXINS AND POISONS FOR THE TREATMENT OF CXCR4 + CANCERESMINECOWorking package
RTC-2014-2207-1TERARMET: Development of therapies for the treatment of rare congenital metabolic diseasesMINECOParticipant
Marato 416/C/2030TV32013-132031Genotoxic nanoparticles targeting colorectal cancer stem cellsMarato TV3Participant

Publications

2016

  • Corchero J.L.. Eukaryotic aggresomes: from a model of conformational diseases to an emerging type of immobilized biocatalyzers. Applied Microbiology and Biotechnology. 2016;100(2):559-569.
  • Saccardo P., Corchero J.L., Ferrer-Miralles N.. Tools to cope with difficult-to-express proteins. Applied Microbiology and Biotechnology. 2016;:1-9.
  • Torrealba D., Seras-Franzoso J., Mamat U., Wilke K., Villaverde A., Roher N. et al. Complex particulate biomaterials as immunostimulant-delivery platforms. PLoS ONE. 2016;11(10)
  • Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.
  • Serna N., Cespedes M.V., Saccardo P., Xu Z., Unzueta U., Alamo P. et al. Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016;12(5):1241-1251.
  • Rueda F., Gasser B., Sanchez-Chardi A., Roldan M., Villegas S., Puxbaum V. et al. Functional inclusion bodies produced in the yeast Pichia pastoris. Microbial Cell Factories. 2016;15(1)
  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Céspedes MV, Unzueta U, Álamo P, Gallardo A, Sala R, Casanova I et al. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models.Nanomedicine : nanotechnology, biology, and medicine. 2016;12(7)
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U1

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

04 Feb

NANBIOSIS Against Cancer

The World Health Organization, the International Cancer Research Center (IARC) and the International Union Against Cancer (UICC) celebrate February 4 of each year as World Cancer Day Every year, 14 million new cases of cancer are diagnosed worldwide and the disease causes 8.2 million deaths. Thanks to scientific research, great advances have been made in the fight against cancer. Through surgery, chemotherapy or radio therapy and, in the last 20 years, through immunotherapy, hormonal treatment or cell therapies, tools have been obtained to improve early diagnosis and treatments, increasing cancer survival by 20%. The only way to understand cancer and,[...]

15 Nov

NANBIOSIS in the Posters presentation in CIBER-BBN ANNUAL CONFERENCE 2018

Last 12 and 13 of November, CIBER-BBN  has celebrated its 12th Annual Conference in Hotel Felipe IV in Valladolid. In poster session participated  NANBIOSIS  itself and some of its units. NANBIOSIS, Infrastructure for the Production & Characterization of Biomaterials, Nanomaterials and medical devices up to preclinical validation. Nanbiosis management team. Divalent cation effects on assembly of histidine-rich protein nanoparticles. López-Laguna, U. Unzueta, O. Conchillo-Solé, A. Sánchez-Chardi, M. Pesarrodona, O. Cano-Garrido, E. Voltà, L. Sánchez-García, N. Serna, P. Saccardo, R. Mangues, A. Villaverde, E. Vázquez (NBT-UAB) (U1 -U18) Antimicrobial peptides (AMPs) anchored on the surface of contact lenses to prevent corneal infections. Emiliano Salvagni, Clara García,[...]

06 Sep

A new pathway for the prevention of metastasis in colorectal cancer in humans is open: a nanomedicine that selectively eliminates metastatic stem cells

Researchers of NANBIOSIS U18  Nanotoxicology Unit and U1. Protein Production Platform (PPP) at the Biomedical Research Institute of Sant Pau (IIB Sant Pau), of the Hospital of Santa Creu i Sant Pau, of the Universitat Autònoma de Barcelona (UAB), the Superior Council of Scientific Research (CSIC) and the Center for Biomedical Research in Network (CIBER) have published an article in one of the most prestigious international scientific journals in the field of Molecular Medicine, EMBO Molecular Medicine. This article demonstrates the efficacy of the  nanopharmaceutical  that selectively removes metastatic stem cells in animal models of colon cancer. The new drug works like a[...]

27 Aug

Recombinant proteins production: optimization strategies.

On October 24th-26th, Aula Científica, in collaboration with IBB, organizes a theorical and practical course on “Recombinant proteins production: optimization strategies“. Some researchers of NANBIOSIS Unit1 Protein Production Platform (PPP), will transmit their knowhow and experience to the attendees, as José Luis Corchero, Rosa Mendoza Moreno and Neus Ferrer Miralles, Scientific Director of the Protein production planform of ICTS NANBIOSIS. The course is aimed at researchers and laboratory technicians from universities, hospitals, companies and research centers who are interested in the expression, production and purification of recombinant proteins with de objectives of analyze and design strategies for the improvement in the expression,[...]

06 Aug

How to optimize strategies to produce recombinant proteins?

Researchers of NANBIOSIS  U1. Protein Production Platform (PPP), organize a course on production of recombinant proteins together with  Aula Científica whose objective is to analyze and design strategies for the improvement in the expression, production and purification of recombinant proteins in heterologous systems. For  further information[...]

24 Jul

The general consul of France meets with NANBIOSIS researchers

The general consul of France in Barcelona, ​​Mr. Cyril Piquemal visited the IBB UAB facilities last July 18, to find out about the research that is being carried out and, in particular, explore possible collaborations in nano-pharmacy development projects. During the visit, the Consul of France in Barcelona was received by Màrius Martínez, Vice President of International Relations at the UAB; Maite Paramio, Deputy Vice President; Ivan Martínez, vice president of Research; Salvador Ventura, director of the Institute of Biotechnology and Biomedicine, and Antonio Villaverde, head of the IBB Nanotechnology Unit-NANBIOSIS  U1. Protein Production Platform (PPP) Next, the mayor visited[...]

22 Jul

Nanomedicine to fight against the spread of cancer

Nanoligent, S.L., the company stablished on March 2017 by professors Dr. A. Villaverde and Dra. E. Vázquez from NANBIOSIS Unit 1, professor Dr. M. Mangués from NANBIOSIS Unit 18, and entrepreneur Dr. M. Rodríguez is highlighted in la Vanguardia. More information here &nbs[...]

U1-Protein Production Platform - PPP
Read More

U2. Custom Antibody Service Unit (CAbS)

U2 CAbS-hybridoma clone
Ciber bbn

U2. Custom Antibody Service (CAbS)

  • Scientific Director: Prof. Pilar Marco pilar.marco@cid.csic.es
  • Scientific Coordinator: Dra. Nuria Pascual npdqob@cid.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC

IQAC CSIC

Order request

Description

The facility is located in the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC; Barcelona). It is equipped with a laboratory for the development and production of monoclonal antibodies. The laboratory is fully equipped for obtaining, selecting and storing monoclonal antibody producing hybridomas. In addition, the facility has infrastructure for the production of polyclonal antibodies, as well as laboratories for the synthesis of bioconjugates, haptens, the purification of antibodies and the performance of immunoassays. In addition to the above mentioned equipment, the IQAC-CSIC provides animal husbandry facilities and a unit for the synthesis of organic molecules.

The equipment consists in an inverted phase contrast microscope with a camera, two Class II laminar flow biological safety cabinets, two CO2 incubators, a bioreactor for hybridoma culture, and tangential filtration unit for purification of the antibodies produced in the culture. Among the items of available equipment it should be highlighted a spotter for selection of high antibody producing cell lines and an automated ELISA microplate washer an ELISA reader, two AKTA Prime Liquid chromatography systems for antibody purification, plus standard equipment (centrifuges, fridges, liquid nitrogen containers, autoclave, baths, and vacuum equipment) and all the necessary routine laboratory apparatus.Cabs also has access to a fully equipped chemistry laboratory for the synthesis of haptens and immunoreagents.

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
SAF2015-67476-R Immunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS) Ministerio de Economía y Competitividad Participant
PIE1400061 Molecular links between diabetes and neurodegenerative diseases ISCIII Oberver
2014SGR1484 Consolidated Research Group Generalitat de Catalunya Participant
FP7-614168 Real time monitoring of SEA contaminants by an autonomous Lab-on-a-Chip biosensor (SEA-on-a-CHIP) European Commission Oberver
CI16-00031 Caixa Impulse A new approach for the detection of Pseudomonas aeruginosa CaixaBank Participant
MSCA-ITN2015-675412 New Diagnostics for Infectious Diseases European Commission Participant
TECCTP15-1-0011 Ajuda acreditació Tecnio del grup Nb4D ACCIÓ: Generalitat de Catalunya Others

Publications

2016

  • Roncador G., Engel P., Maestre L., Anderson A.P., Cordell J.L., Cragg M.S. et al. The European antibody network’s practical guide to finding and validating suitable antibodies for research. mAbs. 2016;8(1):27-36.
  • Pastells C., Pascual N., Sanchez-Baeza F., Marco M.-P.. Immunochemical Determination of Pyocyanin and 1-Hydroxyphenazine as Potential Biomarkers of Pseudomonas aeruginosa Infections. Analytical Chemistry. 2016;88(3):1631-1638.
  • Salvador J.-P., Marco M.-P.. Amperometric Biosensor for Continuous Monitoring Irgarol 1051 in Sea Water. Electroanalysis. 2016;28(8):1833-1838.

News U2

24 Feb

Micro & nano(bio)technology for Diagnosis: Changes and Challenges

Pilar Marco, Scientific Director of NANBIOSIS U2 Custom Antibody Service (CAbS) participated as Keynote speakers at the Second European Biosensor Symposium (EBS2019) taking about “Micro & nano(bio)technology for Diagnosis: Changes and Challenges” at the 2nd European Biosensor Symposium 2019 that took place in Florence (Italy) Last February 18-21. The EBS brougth toguether young scientists, experienced researchersand companies to push forward new approaches on biosensor and and their applications, Pilar Marco spoke abaut the changes ocurred on the field of Diagnosis since the days of “house calls”, relying primarily on physical examination, to nowadays in which a wide portfolio of biochemica[...]

12 Feb

PILAR MARCO, Scientific Director of NANBIOSIS U2, interviewed by CIBER-BBN ISCIII Bulletin

Pilar Marco, Scientific Director of NANBIOSIS U2 Custom Antibody Service (CAbS) has been highlighted in the January Bulletin of CIBER-BBN ISCIII In the interview, among other topics Prof. Pilar Marco talks about diagnostic devices based on nanobiosensors and the extraordinary impact that these technologies could have on health in the coming decades. Her research group Nb4D (Nanobiotechnology for Diagnosis) has an important collection of specific antibodies for different biomarkers and the CIBER-BNN/IQAC-CSIS platform CAbS (Custom Antibody Service) that constitutes the unit 2 of NANBIOSIS, they offer the possibility of producing specific and immunoreactive antibodies with the necessary expertise to generat[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

29 Nov

New device could monitor treatments with anticoagulant to achive personalized therapies

Researchers from NANBIOSIS units 2 and 4 have designed a biosensor device based on gold nanostructures that precisely detects the presence of the anticoagulant drug from a small blood sample. Treatments with anticoagulants such as Sintrom® (acenocoumarol) face the difficulty of adjusting the drug doses. This device will allow patients to self-regulate the dose.   Researchers of NANBIOSIS unit 4  Biodeposition and Biodetection Unit of the Consejo Superior de Investigaciones Científicas (CSIC), the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and CIBER Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) have developed a biosensor device which allows the monitoring of anticoagulants such as Sintrom® (acenocoumarol) to[...]

23 Nov

Two units of NANBIOSIS in the project selected by La Marató TV3 to fight against bacterial infections

La Marató TV3 in its call for biomedical projects in infectious diseases has selected the project “Uses of molecular analysis of Quorum Sensing with the diagnosis of bacterial infections” of the Nb4D group, led by Mª Pilar Marco, Scientific Director of unit 2 of NANBIOSIS and in which Miriam Royo also participates Scientific Coordinator of unit 3 of NANBIOSIS, both in the IQAC-CSIC of Barcelona The project of the Nanobiotechnology for Diagnosis (Nb4D) group of the CSIC and the CIBER-BBN has been selected among more than 200 candidates as a project of scientific excellence to be funded in the ca[...]

15 Nov

NANBIOSIS in the Posters presentation in CIBER-BBN ANNUAL CONFERENCE 2018

Last 12 and 13 of November, CIBER-BBN  has celebrated its 12th Annual Conference in Hotel Felipe IV in Valladolid. In poster session participated  NANBIOSIS  itself and some of its units. NANBIOSIS, Infrastructure for the Production & Characterization of Biomaterials, Nanomaterials and medical devices up to preclinical validation. Nanbiosis management team. Divalent cation effects on assembly of histidine-rich protein nanoparticles. López-Laguna, U. Unzueta, O. Conchillo-Solé, A. Sánchez-Chardi, M. Pesarrodona, O. Cano-Garrido, E. Voltà, L. Sánchez-García, N. Serna, P. Saccardo, R. Mangues, A. Villaverde, E. Vázquez (NBT-UAB) (U1 -U18) Antimicrobial peptides (AMPs) anchored on the surface of contact lenses to prevent corneal infections. Emiliano Salvagni, Clara García,[...]

04 Sep

Nanoplasmonic biosensor device for the monitoring of acenocoumarol therapeutic drug in plasma

As a result of the collaboration carried aout by two units of NANBIOSIS, U4. Biodeposition and Biodetection Unit and U2. Custom Antibody Service (CAbS), it has been developed a compact and simple nanoplasmonic sensing device based on gold nanodisks for the rapid monitoring of acenocoumarol, using highly specific polyclonal antibodies produced against the drug Acenocoumarol (Sintrom®) which implies: A label-free nanoplasmonic device for the rapid monitoring of acenocoumarol in plasmaD. Direct quantification in real time requiring low sample volume is achieved. Non-specific interferences from plasma are minimized using the developed methodology. Excellent accuracy has been observed measuring blind plasma samples. Potential to be implemented as a POC devic[...]

23 Jul

Interferometric nanoimmunosensor for label-free and real-time monitoring of Irgarol 1051 in seawater

As a result of a collaboration in the context of the EC-FP7 program OCEAN 2013, NANBIOSIS Unit 2 Custom Antibody Service (CAbS) and  Unit 4. Biodeposition and Biodetection,  the research groups coordinating this NANBIOSIS Units have recently published an article titled “Interferometric nanoimmunosensor for label-free and real-time monitoring of Irgarol 1051 in seawater” in the scientific magzine  iosensors and Bioelectronics. The CIBER-BBN-ICN2 group  Nanobiosensors and Bioanalytical Applications, led by Prof. Laura Lechuga has developed the immunosensor that is described in the article using immunoreactive, produced in the group of  Nanobiotechnology for Diagnostics Group (Nb4D), led by Prof. Pilar Marco, with the collaboration of CAbS,[...]

U2-Custom Antibody Service (CAbS)
Read More

U3. Synthesis of Peptides Unit

Ciber bbn

U3. Synthesis of Peptides Unit

  • Scientific Director: Prof. Fernando Albericio albericio@ub.edu
  • Scientific Coordinator: Dr. Miriam Royo miriam.royo@iqac.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC

IQAC CSIC

Order request

This Unit is coordinated by the Peptides and Nanoparticles Group at the Parc Científic de Barcelona (PCB) and has the equipment necessary to provide services of synthesis of peptides at different scales (mg to g), purification, characterization, and post-synthesis modification, such as, conjugation to proteins and fluorescent. It counts with laboratories for synthesis and other to carry out modification of the peptides during and post synthesis labels. Also counts with a laboratory equipped with several preparative and analytical chromatography systems for purification and characterization. This facility benefits from the wide experience of Dr. Fernando Albericio in the design and synthesis of peptides with specific biological activity and the introduction of modifications necessary for these peptides to be bound to therapeutic nanoconjugates and other molecules, either to take advantage of the pharmacological activity of the peptide itself or to facilitate the introduction of nanoconjugates or other molecules into the cells in order to reach the therapeutic target. Its location allows the access to the rest of services of the PCB with an occupy area of 5.000m2.

Active projects

Title Fundin: Organism Call: Funding source Role
ICTS-2017-10-CIBER-2 Acquisition and istallation of infrastrucuture to complemntUnis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivoExperiment Ministerio de Economía, Industria y Competitividad (MINECO) Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt) Coordinator
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
SAF2015-67476-R Immunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS) Ministerio de Economía y Competitividad Participant
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant

Publications

2016

  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U3

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

24 Nov

Antimicrobial peptides are a promising kind of molecules to fight multi-drug resistant bacteria

The project titled “Breaking the boundaries of resistance to antimicrobials; searching for new antimicrobials against multiresistant bacteria: work on polycytonic peptides and lipid nanoparticles (BARNAPA)” in which participates Fernando Albericio, Scientific Director of NANBIOSIS unit 3 Synthesis of Peptides Unit, has been selected by La Marató TV3 and finnaced with 383.276,25 €. According to Fernando Albericio, the project arises from the need of effective and safer antibiotics to fight resistant and multi-drug resistant bacteria. In this sens, the proyect developed in collaboration with Miquel Vinyas of the UB and with the Stefania Stefani group of the Universita de Catania  looks at antimicrobia[...]

23 Nov

Two units of NANBIOSIS in the project selected by La Marató TV3 to fight against bacterial infections

La Marató TV3 in its call for biomedical projects in infectious diseases has selected the project “Uses of molecular analysis of Quorum Sensing with the diagnosis of bacterial infections” of the Nb4D group, led by Mª Pilar Marco, Scientific Director of unit 2 of NANBIOSIS and in which Miriam Royo also participates Scientific Coordinator of unit 3 of NANBIOSIS, both in the IQAC-CSIC of Barcelona The project of the Nanobiotechnology for Diagnosis (Nb4D) group of the CSIC and the CIBER-BBN has been selected among more than 200 candidates as a project of scientific excellence to be funded in the ca[...]

22 Nov

Lysosomal Rare Disorders: Focus on Fabry Disease

Last November 19, Vall d’Hebron held a seminar  on Lysosomal Rare Disorders: Focus on Fabry Disease as  part of the Rare Diseases Program at the Vall d’Hebron Campus, in collaboration with the European Commission, the Center for Biomedical Research Network on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) and the CIBBIM-Nanomedicine at Vall d Hebron Research Institute (VHIR) through the Smart-4-Fabry projec In the  second plenary session, moderated by Nora Ventosa and Simó Schwartz, Scientific Directors of NANBIOSIS units 6 and 20 and devoted to New therapeutic strategies for lysosomal disorders, the speakers presented their findings regarding biomarkers, genetic variants and treatment protocols.[...]

24 Aug

Peptides, targeting units and drug conjugates

Miriam Royo, Scientific Coordinator of Unit 3 of NANBIOSIS explains in this video the expertise of the unit in the preparation of difficult peptides (Cyclid and polycyclic peptides, stapled peptides and dificult peptides, depsipetides, natural products and libraries, peptidomimetic libraries, peptides as antigens or adjuvants, tarjeted drug conjugates, etc… as well as therapeutic agen-PEG-targeting unit conjugates[...]

07 Jul

Stimuli-Responsive Functionalization Strategies to Spatially and Temporally Control Surface Properties: Michael vs Diels–Alder Type Additions

NANBIOSIS Unit 6 Biomaterial Processing and Nanostructuring and Unit 3 Synthesis of Peptides collaborate in a research whose results are published by The Journal of Physical Chemistry B Stimuli-Responsive Functionalization Strategies to Spatially and Temporally Control Surface Properties: Michael vs Diels–Alder Type Additions Adriana R. Kyvik, Carlos Luque-Corredera, Daniel Pulido, Miriam Royo, Jaume Veciana, Judith Guasch, and Imma Ratera The Journal of Physical Chemistry B 2018 122 (16), 4481-4490 DOI: 10.1021/acs.jpcb.8b01652 Stimuli-responsive self-assembled monolayers (SAMs) are used to confer switchable physical, chemical, or biological properties to surfaces through the application of external stimuli. To obtain spatially and temporally tunable surfaces, we present microcontact printed SAMs of a hydroquinone molecule that are used[...]

22 Jun

NANOMEDICINE APPLICATIONS IN DRUG DELIVERY AND TARGETING: NANBIOSIS – NANOMED Industrial Forum

Yesterday took place in Barcelona, at Barcelona School of Management, Universitat Pompeu Fabra, a meeting of resarch groups and units of NANBIOSIS and CIBER-BBN and companies in the third B2B Forum organized by NANBIOSIS, in this case together with NANOMED SPAIN. Thirteen companies and twelve groups from CIBER-BBN and CCMIJU (ten of them coordinating NANBIOSIS units) got together to explain, through short presentations of ten minutes, those lines of their work aimed at finding synergies and potential collaborations in the area of Nanomedicine apllications in drug delivery and targeting. There was also a talk by a  representative of CDTI (Spanis[...]

05 Jun

Agreements signed with MINECO for the allocation of FEDER funds for NANBIOSIS ICTS

In the framework of the FEDER Program in ICTS 2014-2020, several projects related to the ICTS NANBIOSIS have been selected by the MINECO for co-financing with FEDER funds of the European Regional Development Funds program. An agreement has been signed between MINECO and CIBER (partner of NANBIOSIS for the co-financing of the Project: “Purchase, installation and set-up of production and characterization equipment to complement the Units: U3-Synthesis of Peptides Unit, U18-Nanotoxicology and U20- In Vivo Experimental Platform”. The total budget of the project amounts to € 307,566.16, with 50% financing with FEDER Funds. Also CSIC (The State Agency Superior Council of[...]

U3-Synthesis of Peptides Unit
Read More

U6. Biomaterial Processing and Nanostructuring Unit

Ciber bbn

U6. Biomaterial Processing and Nanostructuring Unit

 

 

 

    • Scientific Coordinator: Dr. Nathaly Segovia nvsegovia@icmab.es
    • Entities: Instituto de Ciencia de Materiales de Barcelona ICMAB-CSIC
    • Address: Campus de UAB, 08193, Bellaterra, Barcelona, Spain
    • Phone: +34 935 801 853
    • Fax: +34 935 805 729
    • Web: ICMAB

 

 

 

 

 

 

 

ICMAB CSIC

Order request

Custom Gallery: images not found

Description

 

Located at the Instituto de Ciencia de Materiales de Barcelona (ICMAB-CSIC), in Barcelona, and under the coordination of Professor Jaume Veciana and Prof. Nora Ventosa, current directors of NANOMOL Group, which is a research group with wide expertise and recognized excellence in the synthesis, processing and study of molecular and polymeric materials with chemical, electronic, magnetic and biomedical properties.  It gathers several laboratories, perfectly equipped, to perform the mission of this facility: the development, characterization, and large-scale production of molecular biomaterials of therapeutic or biomedical interest, with controlled micro-, nano- and supramolecular structure. One example of Key-Enabling-Technology (KET) available in this unit is a simple one-step methodology, DELOS-SUSP, based on the use of compressed fluids (CF), such as CO2, to prepare particulate materials with precise and reproducible structural characteristics at micro-, nano- and supramolecular levels (size, shape, internal structural gradients, supra­molecular organization and crystalline purity). This example shows one of the singularities of this unit is that counts with CF–based plants at different scales, from mL to L, which allow process development by QbD and process scale-up.

 

 

U6. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
PI15/00272 Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer. Instituto de Salud Carlos III Participant
H2020-MSCA-ITN-2014-642196 Integrated self-assembled SWITCHable systems and materials: towards responsive organic electronics - a multi-site innovative training action i-Switch Unión Europea H2020 Participant
2014 SGR 17 Consolidation Research Group: Molecular Nanociènciai Materials Orgànics (NANOMOL) Generalitat de Catalunya Participant
CTQ2013-40480-R Molecular Bio- and Electro-active materials for the improvement of health and social well-being (Be-Well) MICINN Participant
FP7-PEOPLE-2013-ITN nº 607721 Nanochemistry of molecular materials for 2-photon functional applications. Nano2Fun Unión Europea Participant
MAT2013-50036-EXP Cell Surface Vessel Engineering Using Dynamic Molecular Bioinfecting (DYNAMO) MINECO Participant
RTC-2016-4567-1 Nanocapsules containing active ingredients for the topical treatment of dermatological diseases (NANO4DERM) MINECO Participant
RTC-2014-2183-S Application of Quatsomes technology for the development of a new range of perfumed softeners with lower environmental impact MINECO Participant
201260E080 Self-assembly, Nanostructuring and Processing of Functional Organic Molecules and their Applications Ministerio de Ciencia e Innovación Participant
MAT2016-80826-R Molecular materials and supramolecular organizations for therapy, diagnosis and tissue engineering (MOTHER) MINECO Participant
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant

Publications

2016

 

  • Munoz-Gomez J.L., Monteagudo E., Lloveras V., Parella T., Veciana J., Vidal-Gancedo J.. Optimized polarization build-up times in dissolution DNP-NMR using a benzyl amino derivative of BDPA. RSC Advances. 2016;6(32):27077-27082.
  • Cordoba A., Hierro-Oliva M., Pacha-Olivenza M.A., Fernandez-Calderon M.C., Perello J., Isern B. et al. Direct Covalent Grafting of Phytate to Titanium Surfaces through Ti-O-P Bonding Shows Bone Stimulating Surface Properties and Decreased Bacterial Adhesion. ACS Applied Materials and Interfaces. 2016;8(18):11326-11335.
  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.

2017

  • Grimaldi N., Rojas P.E., Stehle S., Cordoba A., Schweins R., Sala S.et al. Pressure-Responsive, Surfactant-Free CO2-Based Nanostructured Fluids. ACS Nano. 2017;11(11):10774-10784.
  • Silbaugh D.A., Ferrer-Tasies L., Faraudo J., Veciana J., Ventosa N., Korgel B.A. Highly Fluorescent Silicon Nanocrystals Stabilized in Water Using Quatsomes. Langmuir. 2017;33(50):14366-14377.
  • Vinuesa T., Herraez R., Oliver L., Elizondo E., Acarregui A., Esquisabel A. et al. Benznidazolenanoformulates: A chance to improve therapeutics for Chagas disease. American Journal of Tropical Medicine and Hygiene. 2017;97(5):1469-1476.
  • Pesarrodona M., Crosas E., Cubarsi R., Sanchez-Chardi A., Saccardo P., Unzueta U. et al. Intrinsic functional and architectonic heterogeneity of tumor-targeted protein nanoparticles. Nanoscale. 2017;9(19):6427-6435.

News U6

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

04 Feb

NANBIOSIS Against Cancer

The World Health Organization, the International Cancer Research Center (IARC) and the International Union Against Cancer (UICC) celebrate February 4 of each year as World Cancer Day Every year, 14 million new cases of cancer are diagnosed worldwide and the disease causes 8.2 million deaths. Thanks to scientific research, great advances have been made in the fight against cancer. Through surgery, chemotherapy or radio therapy and, in the last 20 years, through immunotherapy, hormonal treatment or cell therapies, tools have been obtained to improve early diagnosis and treatments, increasing cancer survival by 20%. The only way to understand cancer and,[...]

01 Feb

Quatsomes. A new family of nanocarriers for drug delivery

The XXXVII edition of the Biennial Meeting of the Spanish Royal Society of Chemistry (RSEQ) will be held from the 26th to the 30th of May in Donostia-San Sebastian.  Prof. Jaume Veciana, Scientific Director of NANBIOSIS and unit 06  of NANBIOSIS -ICTS  Biomaterial Processing and Nanostructuring Unit, will present on May 28th 2019 a lecture entitled “Quatsomes. A new family of nanocarriers for drug delivery” at the Simposium “From Chemistry to Nanomedicine” (http://bienal2019.com/simposios.php). In this lecture the advantages and disavatages of such a kind of nanocarriers will be presentaed as well as some of their applications as nanomedicines.” Deadline for sending abstracts: January 30 (http://bienal2019.com/en/communications.php)&nbs[...]

22 Nov

Lysosomal Rare Disorders: Focus on Fabry Disease

Last November 19, Vall d’Hebron held a seminar  on Lysosomal Rare Disorders: Focus on Fabry Disease as  part of the Rare Diseases Program at the Vall d’Hebron Campus, in collaboration with the European Commission, the Center for Biomedical Research Network on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) and the CIBBIM-Nanomedicine at Vall d Hebron Research Institute (VHIR) through the Smart-4-Fabry projec In the  second plenary session, moderated by Nora Ventosa and Simó Schwartz, Scientific Directors of NANBIOSIS units 6 and 20 and devoted to New therapeutic strategies for lysosomal disorders, the speakers presented their findings regarding biomarkers, genetic variants and treatment protocols.[...]

31 Oct

FUNCATH: Prevention of infectious diseases with functionalized catheters awarded by La Marató de TV3

FUNCATH project,  coordinated by scientists of NANOMOL  group, led by Dr. Imma Ratera, has been awarded by Fundació La Marató de TV3 . NANOMOL is the research group that coordinates NANBIOSIS U6 Biomaterial Processing and Nanostructuring Unit, from ICMAB-CSIC and CIBER-BBN. Fundació La Marató de TV3 2017 call was dedicated to infectious diseases and awarded 36 projects among the 186 evaluated according to their excellence, methodology and relevance. FUNCATH is the project for Prevention of infections related to vascular catheters by functionalizing catheters impregnated with thermically activatable hydrogels with broad spectrum antimicrobial agents, whose ultimate goal is the development of vascular catheters coated with multibiofunctiona[...]

11 Oct

Nanoparticles characterization techniques of NANBIOSIS unit 6

The Unit 6 of NANBIOSIS, Biomaterial Processing and Nanostructuring Unit, has organized during the days 8 to 11 of October in the ICMAB-CSIC a course of characterization of Nanoparticles showing some of their techniques to the CSIC researchers. Amable Bernabé, the technician of unit 6 of NANBIOSIS has shown the theory and practice of some methods to characterize nanoparticles and how to handle the necessary equipment. Specifically, these techniques were: Dynamic Light Scattering (DLS) with Zetasizer Nano ZS (Malvern Instruments) Size distribution Z Potential Nanoparticle Tracking Analysis (NTA) with Nanosight NS300 (Malvern Instruments) Size distribution Particle concentration Fluorescence Light Scattering (LS) with Mastersizer 2000 (Malvern[...]

17 Sep

Prof. Jaume Veciana, Scientific Director of NANBIOSIS: Olivier Kahn Plenary Lecture speaker at the ICMM 2018

Prof. Jaume Veciana, Scientific Director of NANBIOSIS has been honored with the Olivier Kahn Plenary Lecture given at the 16th International Conference on Molecule-Based Magnets (ICMM 2018), held on September 1-5, 2018, in Rio de Janeiro, Brazil. For further information: click her[...]

25 Aug

Conversion of Biomolecules into pharmaceuticas Leads using nanovesicles

Nathaly Segovia, Scientific coordinator of NANBIOSIS U 6, Biomaterial Processing and naostructuring unit, explains in this video what the objective of her unit , the services they offer and their technologies  in the field of drug delivery.[...]

U6-Biomaterial Processing and Nanostructuring Unit
Read More

U7. Nanotechnology Unit

Ciber bbn

U7. Nanotechnology Unit

IBEC

Order request

Description

The Nanotechnology Platform is part of the institute’s long-term strategic plan to create new Core Facilities in nanofabrication and bionanocharacterization. Currently, the platform is an accessible and versatile research facility featuring 150m2 of class 10,000 cleanroom space and laboratories offering state-of-the-art equipment for the fabrication and characterization of micro- and nanodevices and structures. Our aim is to facilitate advanced research by providing services in the fields of nanoscience and nanotechnology for all academic and industrial researchers. Some of the many areas of application include nanobioengineering, BioMEMS, materials science, tissue engineering, optic and biomaterials. IBEC’s Nanotechnology Platform offers scientific and technological support that includes the design, development and analysis of devices, materials, and processes, so that academic researchers and companies alike may use the platform to develop their innovative ideas.

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
TEC2015-70104-P Microscrofidic 3D platform of Neuronal culture compartmentalized for the study of neurological diseases MINECO Others
COMRDI15-1-0013-09 Advancecat: acceleradora pel desenvolupament de terapies avançades ACCIÓ Participant

Publications

2016

  • Lagunas A., Tsintzou I., Vida Y., Collado D., Perez-Inestrosa E., Pereira C.R. et al. Tailoring RGD local surface density at the nanoscale toward adult stem cell chondrogenic commitment. Nano Research. 2016;:1-13.

News U7

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

06 Feb

STRYKER & NANBIOSIS start a promising line of biomedical research collaboration

On January 23-24th a two-day meeting between NANBIOSIS and Stryker Trauma GmbH, took place at the Carlos III Health Institute, in Madrid, to explore synergies and potential joint initiatives.   Nils Reimers and Robin Buescher from Stryker, presented some of their research and upcoming projects in the field of trauma medical devices, and representatives from NANBIOSIS’ units -Marisa González from U16 Surface Characterization and Calorimetry Unit, Teresa Galán from U7, Nanotechnology Unit, Gemma Pascual from U17 Confocal Microscopy Service, from CIBER-BBN, Marisa García from U28 (Bionand) and José Francisco Guillén and Francisco Sanchez Margallo from the units of the Jesús[...]

03 Aug

Nanopatterns of Surface-Bound EphrinB1 Produce Multivalent Ligand–Receptor Interactions That Tune EphB2 Receptor Clustering

Researchers  of NANBIOSIS U7. Nanotechnology Unit, are coauthors of the article “Nanopatterns of Surface-Bound EphrinB1 Produce Multivalent Ligand–Receptor Interactions That Tune EphB2 Receptor Clustering” published by NanoLetters, ACC Publications. The authors present a nanostructured surface able to produce multivalent interactions between surface-bound ephrinB1 ligands and membrane EphB2 receptors. They have created ephrinB1 nanopatterns of regular size (<30 nm in diameter) by using self-assembled diblock copolymers. Next, they have used a statistically enhanced version of the Number and Brightness technique, which can discriminate—with molecular sensitivity—the oligomeric states of diffusive species to quantitatively track the EphB2 receptor oligomerization process in real time. The results[...]

06 Jul

Josep Samitier, Scientific Director of NANBIOSIS Unit 7, Panelist in a round table about the current situation of biomedical research

Last month NANBIOSIS Unit 7 Nanotechnology Unit Scientific Director Josep Samitier was one of the panelists in a round table organised by the Cercle de Salut, an association devoted to improving the health system so that it may respond adequately to the challenges posed by society. In the discussion at the Parc de Recerca Biomèdica de Barcelona (PRBB) entitled ‘L’excel·lència en la recerca, reptes immediats’, Josep and the other participants – ISGlobal director Antoni Plasencia and IrsiCaixa director Bonaventura Clotet – discussed the current situation of biomedical research in Catalonia. In particular, the hot topic under discussion was the impact that recent[...]

04 Jul

«The combination of nanotechnology with bioengineering and biomedicine allows us to act on the human body on a molecular scale»

Josep Samitier, Scientific Director of NANBIOSIS Unit 7 Nanotechnology Unit, has been highlighted in ‘Dominical’ supplement of the Diari de Girona last week. More information here [...]

10 May

NANBIOSIS U7 Scientific Director, J Samitier and his vision on technology as a source of eternal youth

Josep Samitier, Scientific Director of U7 of NANBIOSIS, Nanotechnology Unit, has been recently featured in an article in the Jornal “El Mundo” Following the publication of the book “The Death of Death” by Jose Luis Cordeiro and David Wood, which says that by 2045 death will optional thanks to new technologies finding a way to cure aging, the article interviewed Josep Samitier, to have a more realistic point of view. The book ‘Death of death’ assures that in 2045 die will be something optional thanks to the new technologies will find a way to cure aging based on success examples[...]

20 Apr

Two Units of NANBIOSIS participates in the CIBERONC – CIBER-BBN collaboratives projects

Scientists from two NANBIOSIS units participate in two of the three projects selected in the Call CIBER-BBN / CIBERONC. On April 13, the 1st CIBERONC – CIBER-BBN Collaborative Projects Forum took place at the National School of Health (Carlos III Health Institute). The purpose of the event was to carry out the resolution of the call for collaborative seed projects between the two areas. During the forum, 12 proposals for collaborative projects were presented, encompassed in four thematic sessions: new nano-devices, new strategies for 3D culture, phototherapy and drug release. All the proposals included the application of some of t[...]

16 Nov

Posters presentation by NANBIOSIS Units in CIBER-BBN ANNUAL CONFERENCE 2017

Last 13 and 14 of November, CIBER-BBN  has celebrated its 11th Annual Conference in Hotel Santemar in Santander. In this conference there was a poster session with the participation of the following Units of NANBIOSIS. Special mention deserves Unit 1 with Neus Ferrer as Director and  Paolo Saccardo as Coordinator (in the picture): Posters: U1. Protein Production Platform (PPP): Engineering protein complexes as nano- or micro-structured vehicles or drugs for human and veterinary medicine. Ugutz Unzueta, Naroa Serna, Laura Sánchez-García, José Vicente Carratalá, Olivia Cano-Garrido, Mercedes Márquez, Paolo Saccardo, Rosa Mendoza, Raquel Díaz, Héctor, López-Laguna, Julieta Sánchez, Anna Obando, Amanda Muñoz, Andrés Cisneros, Eric Voltà, Aida Carreño, José[...]

U7-Nanotechnology Unit
Read More

U9. Synthesis of Nanoparticles Unit

Ciber bbn

U9. Synthesis of Nanoparticles Unit

    • Entities: Institute of Nanoscience of Aragón (INA)
    • Address: R&D Building, Campus Río Ebro, Universidad de Zaragoza. C/Mariano Esquirl S/n, 50018, Zaragoza, Spain
    • Phone: 34 976 761000 ext. 3496

Nanabiosis-logo Universidad de Zarargoza-U9-U13-U27.

Order request

Description

This unit, integrated in the Nanostructured Films and Particles Group at the Institute of Nanoscience of Aragón (INA) coordinated by Dr. Jesús Santamaría, has as objective the synthesis of nanoparticles with applications in biomedicine. The unit provides an automated system for the synthesis of nanoparticles using laser-induced pyrolysis of chemical precursors in gas and/or aerosol phase, which enable either individual nanoparticles or biocompatible hybrid nanostructures to be produced in large quantities. In addition, this facility is able to draw on a wide range of nanoparticles fabrication technique, as well as having the necessary specialized personnel, to undertake exhaustive characterization of the microstructure, chemical composition, particles size and distribution of sizes, as well as magnetic, optical and colloidal properties and degree of biological functionality of the synthesized material.

U9. Services & Rates

Equipments

In addition to this there is immediate access to advanced electron microscopies (SEM, TEM, HRTEM, UHRTEM), as well as other surface analysis and characterization equipment (XPS, XRD, FTIR, magnetic characterization). The equipment available makes this Unit unique to produce a wide variety of nanoparticles, , inorganic, polymeric, or multifunctional hybrid nanocomposites.

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
CTQ2014-52384-R INTELLIGENT APPLICATIONS BASED ON NANOSTRUCTURED FIBERS CONTAINING NATURAL BIOCIDES WITH PHARMACOKINETIC CONTROL OF THEIR RELEASE Ministerio de Economia y Competitividad Participant
CTQ2013-49068-C2-1-R MICROSYSTEMS BASED ON NANOSTRUCTURES WITH SPECIFIC PROPERTIES OF ADSORPTION AND SUPERFICIAL PLASMON, FOR DETECTION OF HIDDEN EXPLOSIVES AND AGENTS OF CHEMICAL WAR. Ministerio de Economia y Competitividad Participant
TARMAC TARMAC. New tools for the diagnosis and treatment of respiratory infectious diseases: pH-responsive matryoshka nanoparticles for an efficient and controlled intracellular delivery of oral antibiotics and gated nanoparticles for the detection of pathogenic microorganisms showing intracellular persistence Ministerio de Economia y competitividad Participant
TARMAC/IQMA-UDM-UPV pH-responsive matryoshka nanoparticles for an efficient and controlled intracellular delivery of oral antibiotics and gated nanoparticles for the detection of pathogenic microorganisms showing intracellular persistence CIBER-BBN-CIBERES-SEPAR Participant
H2020-MSCA-ITN-2016/H2020-MSCA-ITN-2016 European Training Network for Continuous Sonication and Microwave Reactors. Unión Europea Participant
H2020-SPIRE-2014-2015 ADREM / Adaptable Reactors for Resource- and Energy-Efficient Methane Valorisation Unión Europea Participant
I-2012/023 Development of a microfluidic platform to produce nanomaterials and assessment on new nanotechnology applications Unión Europea Participant
CTQ2016-77147-R NEW STRATEGIES FOR CO2 CONVERSION USING CATALYSTS UNDER ELECTROMAGNETIC RADIATION. MINECO. MINISTERIO DE ECONOMIA Y COMPETITIVIDAD Participant
CTQ2016-79419-R ADVANCED ADSORPTION TECHNOLOGIES, SERS DETECTION AND CATALYSIS FOR CHEMICAL WAR MINECO. MINISTERIO DE ECONOMIA Y COMPETITIVIDAD Participant
NANOHEDONISM A photo-triggered on-demand drug delivery system for chronic pain European Research Council Participant
I-2011/004 HECTOR- MICROWAVE-ASSISTED MICROREACTORS: DEVELOPMENT OF A HIGHLY EFFICIENT GAS PHASE CONTACTOR WITH DIRECT CATAYST HEATING Unión Europea Participant
FIS PI15/01118 Towards an advanced therapy of bone regeneration: tissue intermediates activated by infrared energy for the controlled expression of osteogenic and angiogenic factors INSTITUTO DE SALUD CARLOS III Others
AMBIT Animal Model of Bone Regeneration Induced by Tissue Intermediates Responsive to Near-Infrared Light Roche Farma Participant

Publications

2016

  • Sebastian V., Smith C.D., Jensen K.F.. Shape-controlled continuous synthesis of metal nanostructures. Nanoscale. 2016;8(14):7534-7543.

News U9

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

09 Oct

Researchers of NANBIOSIS U9 awarded for a work on scaffolds for dental regeneration

Researchers Manuel Arruebo and Víctor Sebastián, from the CIBER-BBN group led by Jesús Santamaría (NFP) at the University of Zaragoza, that coordinates NANBIOSIS Unit 9 Synthesis of Nanoparticles, have received the second prize of the Resomer Awards granted by the company Evonik, a international recognition to competitiviness. Their work “Promoting bioengineered tooth innervation using nanostructured and hybrid scaffolds”, has been published in the journal Acta Biomaterialia 50 (2017) 493-501. In this work, the researchers of the CIBER-BBN manufactured biodegradable materials such as scaffolds to promote dental regeneration. These scaffolds contained an immunosuppressive drug that, in addition to avoiding rejection after implantation,[...]

23 Aug

Advanced methods of continuous production of Nanomaterials

Victor Sebastian, researcher of  NANBIOSIS Unit 9 Synthesis of Nanoparticles Unit, explains the production technologies in continuous (Microfluidic systems liquid phase or pyrolysis activated by laser, gas phase in which the nanoparticles are produced)[...]

11 Jul

Jesús Santamaría, interviewed in the Cadena Ser Radio, denounces the bureaucratic barriers that hinder research.

Jesús Santamaría, Scientific Director of NANBIOSIS Unit 9, Synthesis of Nanoparticles Unit, denounces the bureaucratic obstacles of the Law of Contracts, which are paralyzing the investigations whenever it is necessary to buy material or hire personnel.  His research against cancer, which received one of the most powerful European funding of more than two million euros, is stranded because of this rule, which requires to take out any purchase over 15,000 euros. “You can not do research like that,” Santamaría said. “In other countries there are no obstacles and we have to compete with them” With the entry into force on March 9 of[...]

08 Jul

New cover ACS Sustainable Che. Eng. by Scientists of NANBOSIS U9

Scientists of NANBIOSIS Unit 9 Synthesis of Nanoparticles Unit are coauthors of  of the New cover ACS Sustainable Chem. Eng. Sustainable Production of Drug-Loaded Particles by Membrane Emulsification. Albisa A, Piacentini E, Arruebo M, Sebastian V, Giorno L. ACS Sustainable Chem. Eng., 2018, 6 (5), pp 6663–6674 March 13, 2018. DOI: 10.1021/acssuschemeng.8b00401. IF: 5,951[...]

22 Jun

NANOMEDICINE APPLICATIONS IN DRUG DELIVERY AND TARGETING: NANBIOSIS – NANOMED Industrial Forum

Yesterday took place in Barcelona, at Barcelona School of Management, Universitat Pompeu Fabra, a meeting of resarch groups and units of NANBIOSIS and CIBER-BBN and companies in the third B2B Forum organized by NANBIOSIS, in this case together with NANOMED SPAIN. Thirteen companies and twelve groups from CIBER-BBN and CCMIJU (ten of them coordinating NANBIOSIS units) got together to explain, through short presentations of ten minutes, those lines of their work aimed at finding synergies and potential collaborations in the area of Nanomedicine apllications in drug delivery and targeting. There was also a talk by a  representative of CDTI (Spanis[...]

09 Jun

SINO-SPAIN Biomedical and Pharmaceutical Conference with NANBIOSIS participation

Last 7 June 2018 took place in Zaragoza, the Sino-Spain Biomedical and Pharmaceutical Conference, as a result of years of cooperation with Chinese institutions, organizad by Zaragoza University  and Aragonese Foundation for Research & Development of Aragon Government (ARAID), to promote initiatives and foster bilateral collaboration in biomedical and pharmaceutical sectors between Spain and China. The themes of the forum were: Molecular engineering for biomedical products Diagnoses &Design for new devices for medical uses Tissue Engineering and regenerative medicine Pharmacology and nanometerials for medical application Advanced therapies for cancer research   Researcher of three units of NANBIOSIS partcipated in the Conference: from U13. Tissue &am[...]

07 May

Conference on Nanotoxicity, next May 24, Parc Scientific of Barcelona

NANBIOSIS is organizing a Conference on Nanotoxicity in collaboration with Nanomed Spain and Materplat, next May 24 in the Parc Scientific of Barcelona, to debate about the efect of nanotoxicity of nanoparticles and nanotechnologies in health. The increase of potential risks to health has created the new discipline of nanotoxicity, that is, the study of the toxicity produced by the effect of nanoparticles and nanomaterials. The objective of this day is to learn more about the lines that are being followed by researchers in the area of ​​nanotoxicity, the progress of different projects in this field, as well as existing[...]

U9-Synthesis of Nanoparticles Unit
Read More

U10. Drug Formulation

Ciber bbn

U10. Drug Formulation

  • Scientific Director: Prof. José Luis Pedraz joseluis.pedraz@ehu.es
  • Scientific Coordinator: Dr. Jesús Ciriza Astrain jeciriza@gmail.com
  • Entities: Universidad del País Vasco (UPV/EHU)
  • Address: Pharmacy & Pharmac. Technology Lab.; Facultad de Farmacia, C/Paseo de la Universidad 7, 01006 Vitoria-Gasteiz (Spain)
  • Phone: +34 945 013091
  • Fax: +34 945 013040
  • Web: NANOBIOCEL UPV/EHU

UPV-EHU

Order request

Description

Located at the Faculty of Pharmacy, University of the Basque Country (UPV), Campus of Vitoria, is led by Prof. José Luis Pedraz and consists of large laboratories for: cell culture, chromatography equipment, sample preparation and characterization and one specific for scale preparation of pharmaceutical formulations. This Unit has the capacity to design and evaluate dosage forms both classical and new dosage forms of biotech drugs, DNA, RNA and vaccines using different methodologies based on micro and nano-medicine. The latter methodology based on the microencapsulation of cells, peptides, proteins, and in general of biotech products, as well as the development and design of non-viral vectors for gene therapy, is one of the biggest singularities of this unit. It counts with the most advanced equipment for micro and nano encapsulation.

The aim of the Unit is to determine experimentally all the variables needed to develop an optimal formulation and work instructions for preparing final pharmaceutical products.

The pharmaceutical technology applied to drug development involves the selection of materials and procedures that can be adapted to different processes that lead to specific pharmaceutical forms. To do that, the Unit counts with the most advanced equipment to cover the development for all the steps of the process.

One of the singularities of this Units is that is GLP certified by the Spanish Medicament Agency

U10. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
RTC-2016-4770-1 Development of a new bioadhesive for the treatment of Pterigium. Biotape
Ministerio de Economía, Industría y Competitividad (MINECO) Retos Colaboración 2016 Partner
RTC-2016-5451-1 Development of Bioprinting and Bioink systems for cartilage and bone repair
Ministerio de Economía, Industria y Competitividad (MINECO) Retos Colaboración 2016 Partner
GA: 783132 POSITION-II “A pilot line for the next generation of smart catheters and implants”
Electronic Component Systems for European Leadership Joint Undertaking (JU) - ECSEL JU H2020-ECSEL-2017-1-IA-two-stage Partner
GA: 645991 DRIVE – Diabetes-Reversing Implants for Enhanced viability and long-term efficacy Unión Europea (Comisión Europea) H2020-NMP-2014-two-stage Partner
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
RTC-2016-4770-1 DEVELOPMENT OF A NEW BIOADHESIVE FOR PTERIGIUM SURGERY. BIOTAPE MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD. Participant
RTC-2016-5451-1 DEVELOPMENT OF BIOIMPRESSION SYSTEMS AND BIOTINES FOR THREE-DIMENSIONAL CARTILAGE AND BONE REGENERATION MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD. Participant
RTC-2015-3303-1 Lipid solid nanoparticles for subcutaneous administration of antitumor marine compounds - UNDERLIPIDS MINISTERIO DE ECONOMIA Y COMPETITIVIDAD

Publications

2016

  • Grijalvo S., Puras G., Zarate J., Pons R., Pedraz J.L., Eritja R. et al. Nioplexes encapsulated in supramolecular hybrid biohydrogels as versatile delivery platforms for nucleic acids. RSC Advances. 2016;6(46):39688-39699.
  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Fleischer A. et al. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. International Journal of Pharmaceutics. 2016;498(1-2):263-273.
  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Bachiller D. et al. Stability study of sodium colistimethate-loaded lipid nanoparticles. Journal of Microencapsulation. 2016;33(7):636-645.
  • Garcia-Orue I., Gainza G., Gutierrez F.B., Aguirre J.J., Evora C., Pedraz J.L. et al. Novel nanofibrous dressings containing rhEGF and Aloe vera for wound healing applications. International Journal of Pharmaceutics. 2016;:-.
  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The role of helper lipids in the intracellular disposition and transfection efficiency of niosome formulations for gene delivery to retinal pigment epithelial cells. International Journal of Pharmaceutics. 2016;503(1-2):115-126.
  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The influence of the polar head-group of synthetic cationic lipids on the transfection efficiency mediated by niosomes in rat retina and brain. Biomaterials. 2016;77:267-279.

News U10

22 Aug

Micro and nanotechnologies for the release of biotechnological products

José Luis Pedraz, Scientific Director of NANBIOSIS Unit 10, Drug formulation, talks in this video about Micro and polymeric nanoparticles, lipid nanoparticles, non-viral vectors for gene therapy and scaffolds for cell therapy and regenerative medicine and bio 3D printing &nbs[...]

22 Jun

NANOMEDICINE APPLICATIONS IN DRUG DELIVERY AND TARGETING: NANBIOSIS – NANOMED Industrial Forum

Yesterday took place in Barcelona, at Barcelona School of Management, Universitat Pompeu Fabra, a meeting of resarch groups and units of NANBIOSIS and CIBER-BBN and companies in the third B2B Forum organized by NANBIOSIS, in this case together with NANOMED SPAIN. Thirteen companies and twelve groups from CIBER-BBN and CCMIJU (ten of them coordinating NANBIOSIS [...]

20 Jun

NANBIOSIS working on the development of next generation catheters

NANBIOSIS’ partners CIBER-BBN and JUMISC, with another 44 European partners, led by Philips Electronics Nederland B.V, will work on the development of next genration catheters.  The project, Position-II  (Ref. n. 783132), that pretends to diversify the production of smart catheters (overcoming the obsolescence of current ones), improve their performance (facilitating their use to be smaller), [...]

03 Jun

DRIVE Project: Artificial Biopancreas for Type I Diabetics

On Saturday, June 2, in the auditorium of the Artium museum in Vitoria, a meeting was held for patients with diabetes, organized by the group of European researchers of the DRIVE project with the aim of conecting patiens with researchers. The event was organized by the NanoBioCel research group of the CIBER-BBN and the University of [...]

28 May

New frontiers in the treatment of Diabetes type 1

On Saturday, June 2, at 10.30 in the auditorium of the Artium Museum in Vitoria-Gasteiz, a meeting will take place for patients with diabetes, organized by the group of European researchers of the DRIVE project. The objective of the meeting, held for the first time in Spain, is to connect researchers with all those with [...]

15 May

Nanotechnology, gene therapy, omics therapies and ‘big data’

Nanotechnology, gene therapy, omics therapies and ‘big data’ were the topics discussed in the Forum on Emerging Technologies oganized on May 8 by nanotechnology, gene therapy, omics therapies and ‘big data’ were the topics discussed in the I Forum on Emerging Technologies held on May 8, organized by the CIBER Internationalization Platform, of which the CIBERER, [...]

05 May

Gene therapy in pseudohypoparathyroidism

In 1942, Albright and colleagues described the first hormone resistance syndrome, which they called pseudohypoparathyroidism (PHP) (1), patients had a specific phenotype consisting of short stature, central obesity, round face, short neck and brachydactyly, which is what that today we know like Albright Hereditary Osteodystrophy (AHO, Albright Hereditary Osteodystrophy). Nanobiocel research group, coordinator of NANBIOSIS U10. [...]

30 Apr

I Forum on Emerging Technologies organized by CIBER

On May 8th, will take place in Madrid, at the Assembly Hall Ernest Lluch of the Instituto de Salud Carlos III, organized by CIBER Internationalization Platform (CIBER-BBN, CIBERER, CIBERES) the I Forum on Emerging Technologies. The objective of this meeting is to promote the exchange of ideas and scientific knowledge among the CIBER research groups with the [...]

02 Mar

NANBIOSIS Unit 10 of Drug Formulation participates in the European Project Position II

Nanobiocel, the CIBER-BNN – UPV-EHU group, led by José Luis Pedraz, Scientific Director of NANBIOSIS-ICTS U10 “Drug Formulation Unit” participates in the Position II European project, coordinated by Philips Electronics Nederland. The project, funded through the Horizon 2020 call with a global budget of more than 50 million euros, will be developed during three years [...]

23 Feb

NANBIOSIS ICTS invites groups and companies to discuss Smart Biomaterials and devices for Drug Delivery

On February 22nd, the National School of Health of the Carlos III Health Institute hosted the forum on Smart Biomaterials and biomedical devices for applications in drug delivery and regenerative medicine, organized by the ICTS Nanbiosis, an infrastructure shared by the CIBER-BBN and the Center of Minimally Invasive Surgery Jesus Usón (CCMIJU). This is the [...]

U10-Drug Formulation
Read More

U12. Nanostructured liquid characterization unit

Ciber bbn

U12. Nanostructured liquid characterization unit

  • Scientific Director: Prof. Carlos Rodríguez cranqb@cid.csic.es
  • Scientific Coordinator: Jordi Esquena jemqci@iqac.csic.es
  • Entities: Colloid and Interfacial Chemistry Group (QCI) at the Institute of Advanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 159
  • Web: QCI – IQAC- CSIC

IQAC CSIC

Order request

Description

The unit is located at the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), in Barcelona and it is coordinated by the Colloidal and Interfacial Chemistry Group, led by Dr. Carlos Rodríguez. The unit is focused on the characterization of nanostructures in liquids and liquid/liquid interfaces, such as micelles, liposomes, micro- and nano-emulsions, and nanoparticles. The unit features state-of-the-art instrumentation for the determination of various parameters such as size distribution and zeta potential (surface charge), critical micelle concentration (CMC), solubilization capacity, osmolarity, surface and interfacial tension, wettability, refractive index, turbidity, colloidal stability, density, viscosity and other rheological parameters (shear and elastic moduli, critical yield stress, etc.)

U12. Services & Rates

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
CTQ2014-52687-C3-1-P Design and applications of new biocompatible micro / nanogels obtained by advanced condensation methods (MICRONANOGELES) MINECO Participant
2014SGR1655 Grants for consolidated Research Groups of Catalonia Generalitat de Catalunya Participant
FP7-PEOPLE-2013-ITN - 606713 Biopolymer Based FOOd Delivery Systems (BIBAFOODS) Unión Europea Participant
Plan de Actuación 2015 Agreement of ACC1Ó with the UAB, the PRUAB, the CSIC and the CVC for the promotion of the technological transfer Generalitat de Catalunya Participant
TECSPR14-2-0033 Theranostic Magnetic Nanoparticles For Cancer Diagnosis and Treatment: Magnetic Properties and Controlled Release of Anticancer Drugs (TheraMagNano) Unión Europea Participant
TECSPR14-2-0044 Novel antimicrobial hydrogels for contact lenses (HYDROLENSES) Unión Europea Participant
Acción COST CM1101 Joint Meeting of WG 3 and WG 4. Workshop "Nano-biocolloidal materials and non-equilibrium self-assembly" Unión europea Participant
Ref.: 308810 076/2015 DEVELOPMENT OF INNOVATIVE FORMULATIONS FOR THE DELIVERY OF ACTIVITIES INTO THE SKIN (ES) ALMIRALL Participant

Publications

2016

  • Fornaguera C., Caldero G., Solans C.. Electrolytes as a tuning parameter to control nano-emulsion and nanoparticle size. RSC Advances. 2016;6(63):58203-58211.
  • Caldero G., Montes R., Llinas M., Garcia-Celma M.J., Porras M., Solans C.. Studies on the formation of polymeric nano-emulsions obtained via low-energy emulsification and their use as templates for drug delivery nanoparticle dispersions. Colloids and Surfaces B: Biointerfaces. 2016;145:922-931.
  • Fornaguera C., Feiner-Gracia N., Caldero G., Garcia-Celma M.J., Solans C.. PLGA nanoparticles from nano-emulsion templating as imaging agents: Versatile technology to obtain nanoparticles loaded with fluorescent dyes. Colloids and Surfaces B: Biointerfaces. 2016;147:201-209.
  • Magana J.R., Kolen’Ko Y.V., Deepak F.L., Solans C., Shrestha R.G., Hill J.P. et al. From Chromonic Self-Assembly to Hollow Carbon Nanofibers: Efficient Materials in Supercapacitor and Vapor-Sensing Applications. ACS Applied Materials and Interfaces. 2016;8(45):31231-31238.
  • Perez-Carrillo L.A., Vilchez S., Mosa J., Aparicio M., Castro Y., Duran A. et al. Synthesis and properties of TiO2-P2O5 and SiO2-TiO2-P2O5 porous hybrids obtained by templating in highly concentrated emulsions. Ceramics International. 2016;42(16):18965-18973.

News U12

15 Nov

NANBIOSIS in the Posters presentation in CIBER-BBN ANNUAL CONFERENCE 2018

Last 12 and 13 of November, CIBER-BBN  has celebrated its 12th Annual Conference in Hotel Felipe IV in Valladolid. In poster session participated  NANBIOSIS  itself and some of its units. NANBIOSIS, Infrastructure for the Production & Characterization of Biomaterials, Nanomaterials and medical devices up to preclinical validation. Nanbiosis management team. Divalent cation effects on assembly of histidine-rich protein nanoparticles. López-Laguna, U. Unzueta, O. Conchillo-Solé, A. Sánchez-Chardi, M. Pesarrodona, O. Cano-Garrido, E. Voltà, L. Sánchez-García, N. Serna, P. Saccardo, R. Mangues, A. Villaverde, E. Vázquez (NBT-UAB) (U1 -U18) Antimicrobial peptides (AMPs) anchored on the surface of contact lenses to prevent corneal infections. Emiliano Salvagni, Clara García,[...]

31 Jul

Advanced encapsulation technologies

Researchers of NANBIOSIS  U12. Nanostructured liquid characterization unit, organize a course on advanced encapsulation technologies together with the Consorci Universitat Internacional Menéndez Pelayo Barcelona (CUIMPB) – Center Ernest Lluch whose objective is to provide attendees with the basic concepts about micro and nanoencapsulation techniques,including fundamentals and methods of preparation, as well as new applications in the chemical, cosmetic and pharmaceutical fields, among others. For  further information and program[...]

22 Jun

NANOMEDICINE APPLICATIONS IN DRUG DELIVERY AND TARGETING: NANBIOSIS – NANOMED Industrial Forum

Yesterday took place in Barcelona, at Barcelona School of Management, Universitat Pompeu Fabra, a meeting of resarch groups and units of NANBIOSIS and CIBER-BBN and companies in the third B2B Forum organized by NANBIOSIS, in this case together with NANOMED SPAIN. Thirteen companies and twelve groups from CIBER-BBN and CCMIJU (ten of them coordinating NANBIOSIS units) got together to explain, through short presentations of ten minutes, those lines of their work aimed at finding synergies and potential collaborations in the area of Nanomedicine apllications in drug delivery and targeting. There was also a talk by a  representative of CDTI (Spanis[...]

01 Jun

Effect of Surface Chemistry and Associated Protein Corona on the Long-Term Biodegradation of Iron Oxide Nanoparticles In Vivo

The results of the research carried out by Scientists of U12. Nanostructured liquid characterization unit, and CIBER-BNN, have been published in an article by ACS Applied Materials & Interfaces: DOI: 10.1021/acsami.7b18648[...]

14 May

Formulated Products: Enabling innovation through value chain and cross-sector collaboration

NANBIOSIS Unit 12. “Nanostructured liquid characterization unit” is co-organizing, next 28th May 2018, in Barcelona, the Workshop “Enabling Innovation through Value Chain and Cross-sector Collaboration” corresponding to the 5th Event of the Regional workshop series of the AceForm4.0 consortium (a coordination and support action (CAS) funded by the European Commission). This event targets industrial and academic players interested in bringing formulation technologies to the next level through collaboration. The main purpose of the day is to validate the recommendations that will be presented to the European Commission (EC) as to what are the areas of research that should be prioritized in the coming framework[...]

14 Mar

Influence of polymer concentration on the properties of nano-emulsions and nanoparticles obtained by a low-energy method

Scientists of NANBIOSIS U12. Nanostructured liquid characterization unit have recently published an article in  Colloids and Surfaces A: Physicochemical and Engineering Aspects For further information &nbs[...]

23 Feb

NANBIOSIS ICTS invites groups and companies to discuss Smart Biomaterials and devices for Drug Delivery

On February 22nd, the National School of Health of the Carlos III Health Institute hosted the forum on Smart Biomaterials and biomedical devices for applications in drug delivery and regenerative medicine, organized by the ICTS Nanbiosis, an infrastructure shared by the CIBER-BBN and the Center of Minimally Invasive Surgery Jesus Usón (CCMIJU). This is the first groups/companies meeting organized by Nanbiosis, in which about 70 B2B meetings  were held. The meeting brought together about 40 participants from 14 research groups (from the CIBER-BBN and the CCMIJU) and 10 companies, which discussed the latest advances in the research lines developed by the groups[...]

25 Jan

Novel synthetic routes as potential multifunctional theranostic nanodevices

Carlos Rodriguez-Abreu, Scientific Director of NANBIOSIS Unit 12 is co-author of the publication “Novel synthetic routes of large-pore magnetic mesoporous nanocomposites (SBA-15/Fe3O4) as potential multifunctional theranostic nanodevices” by “Journal of Materials Chemistry B”. For further information &nbs[...]

U12-Nanostructured liquid characterization unit
Read More

U18. Nanotoxicology Unit

Ciber bbn

U18. Nanotoxicology Unit

  • Scientific Director: Prof. RamonMangues rmangues@santpau.cat
  • Scientific Coordinator: Mª Virtudes Céspedes  mcespedes@santpau.cat
  • Entities: Institut de Recerca. Hospital de la Santa Creu i Sant Pau & Institut de Recerca de Hospital Universitari Vall D’Hebron
  • Address: Hospital Santa Pau. c/Sant Antoni M. Claret, 167, 08025, Barcelona, Spain | Hospital Universitari Vall d’Hebron. Passeig Vall D’Hebron, 119-129, 08035, Barcelona, Spain
  • Phone: +34 935 537 918
  • Web: WEB

Vall-d´Hebrón SAN-PAU

Order request

Active projects

Title Fundin: Organism Call: Funding source Role
ICTS-2017-10-CIBER-2 Acquisition and istallation of infrastrucuture to complemntUnis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivoExperiment Ministerio de Economía, Industria y Competitividad (MINECO) Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt) Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
PI15/00378 Intelligent nanoconjugates for targeted therapy of metastatic colorectal cancer (CRC) Instituto de Salud Carlos III Working package
PIE15/00028 Targeted nanocongugates for the selective elimination of stem cells in disseminated cancer Instituto de Salud Carlos III Working package
PI15/00272 Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer. Instituto de Salud Carlos III Participant
CP15/00163 Maria Virtudes Céspedes Navarro Contracts Miguel Servet Type I Instituto de Salud Carlos III Working package
CD14/00055 Contract SARA BORRELL Instituto de Salud Carlos III Working package
Marato 416/C/2030TV32013-132031 Genotoxic nanoparticles targeting colorectal cancer stem cells Marato TV3 Participant

Publications

2016

  • Cespedes M.V., Guillen M.J., Lopez-Casas P.P., Sarno F., Gallardo A., Alamo P. et al. Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gem;citabine, in pancreatic adenocarcinoma mouse models. DMM Disease Models and Mechanisms. 2016;9(12):1461-1471.
  • Rueda F., Cespedes M.V., Sanchez-Chardi A., Seras-Franzoso J., Pesarrodona M., Ferrer-Miralles N. et al. Structural and functional features of self-assembling protein nanoparticles produced in endotoxin-free Escherichia coli. Microbial Cell Factories. 2016;15(1):-.
  • Céspedes MV, Unzueta U, Álamo P, Gallardo A, Sala R, Casanova I et al. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models.Nanomedicine : nanotechnology, biology, and medicine. 2016;12(7):-.
  • Cespedes M.V., Fernandez Y., Unzueta U., Mendoza R., Seras-Franzoso J., Sanchez-Chardi A. et al. Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs. Scientific Reports. 2016;6:-.
  • Vazquez E., Mangues R., Villaverde A.. Functional recruitment for drug delivery through protein-based nanotechnologies. Nanomedicine. 2016;11(11):1333-1336.
  • Serna N., Cespedes M.V., Saccardo P., Xu Z., Unzueta U., Alamo P. et al. Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016;12(5):1241-1251.
  • Cano-Garrido O, Céspedes MV, Unzueta U, Saccardo P, Roldán M, Sánchez-Chardi A et al. CXCR4(+)-targeted protein nanoparticles produced in the food-grade bacterium Lactococcus lactis.Nanomedicine (London, England). 2016;11(18):-.
  • Rueda F., Gasser B., Sanchez-Chardi A., Roldan M., Villegas S., Puxbaum V. et al. Functional inclusion bodies produced in the yeast Pichia pastoris. Microbial Cell Factories. 2016;15(1):-.
  • Pesarrodona M., Fernandez Y., Foradada L., Sanchez-Chardi A., Conchillo-Sole O., Unzueta U. et al. Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria. Biofabrication. 2016;8(2):-.

Description

This Unit is located in the Hospital de la Santa Creu i Sant Pau, in Barcelona, and is coordinated by Dr. Ramón Mangues, PI of the Oncogenesis and Antitumor Drug Group. The main objective of the Nanotoxicology Unit is to assess the toxicity of new drugs, nanoparticles or nanotechnology-based biomaterials in in vitro and in vivo systems, with the goal of optimizing lead compounds and identifying those with the highest probability of success in the preclinical programme due to their greater safety and tolerability or reduced toxicity. The Unit has rooms equipped for cell culture, for cryopreservation of samples and cell lines, and for sample preparation and analysis and animal facilities for in vivo experimentation.

Equipment: The Unit has access to flow cytometers, sorters, confocal microscope and other equipment of the Platforms available at the Hospital Research Institute as well as housing facilities for small rodents (rat and mouse).

U18-Nanotoxicology Unit
Read More